Patients with diabetes undergoing PCI have less target lesion failure with amphilimus-eluting stents
Patients with diabetes undergoing percutaneous coronary intervention (PCI) have lower target lesion failure rates with amphilimus-eluting stents compared to zotarolimus-eluting stents. At one year, amphilimus-eluting stents met the criteria for noninferiority and superiority over zotarolimus-eluting stents.